Summary
Global Markets Direct’s, ‘Allergic Conjunctivitis - Pipeline Review, H1 2016’, provides an overview of the Allergic Conjunctivitis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Allergic Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Allergic Conjunctivitis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Allergic Conjunctivitis
- The report reviews pipeline therapeutics for Allergic Conjunctivitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Allergic Conjunctivitis therapeutics and enlists all their major and minor projects
- The report assesses Allergic Conjunctivitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Allergic Conjunctivitis
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Allergic Conjunctivitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Allergic Conjunctivitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Accolade Pharmaceuticals, LLC
Akari Therapeutics, Plc
Aldeyra Therapeutics, Inc.
Allergan Plc
Biogen, Inc.
Griffin Discoveries BV
NicOx S.A.
Ocular Therapeutix, Inc.
Ohr Pharmaceutical Inc.
Sylentis S.A.U.
Xencor, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Allergic Conjunctivitis Overview 8
Therapeutics Development 9
Pipeline Products for Allergic Conjunctivitis - Overview 9
Pipeline Products for Allergic Conjunctivitis - Comparative Analysis 10
Allergic Conjunctivitis - Therapeutics under Development by Companies 11
Allergic Conjunctivitis - Therapeutics under Investigation by Universities/Institutes 12
Allergic Conjunctivitis - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Allergic Conjunctivitis - Products under Development by Companies 16
Allergic Conjunctivitis - Products under Investigation by Universities/Institutes 17
Allergic Conjunctivitis - Companies Involved in Therapeutics Development 18
Accolade Pharmaceuticals, LLC 18
Akari Therapeutics, Plc 19
Aldeyra Therapeutics, Inc. 20
Allergan Plc 21
Biogen, Inc. 22
Griffin Discoveries BV 23
NicOx S.A. 24
Ocular Therapeutix, Inc. 25
Ohr Pharmaceutical Inc. 26
Sylentis S.A.U. 27
Xencor, Inc. 28
Allergic Conjunctivitis - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
AGN-229666 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
AL-53817 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
cetirizine hydrochloride - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
dexamethasone acetate SR - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Drugs for Allergic Conjunctivitis - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
GD-134 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
GD-136 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
isunakinra - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
NS-2 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
OPX-1 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
PRT-2761 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Small Molecules to Antagonize Histamine H1 and H4 Receptor for Ophthalmology and Asthma - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
SYL-116011 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
XmAb-7195 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Zafi-2 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Allergic Conjunctivitis - Recent Pipeline Updates 55
Allergic Conjunctivitis - Dormant Projects 69
Allergic Conjunctivitis - Discontinued Products 71
Allergic Conjunctivitis - Product Development Milestones 72
Featured News & Press Releases 72
Feb 29, 2016: Aldeyra Therapeutics Reports Positive Results From Phase IIa Clinical Trial in Subjects With Allergic Conjunctivitis 72
Jan 15, 2016: Eleven Biotherapeutics Reports Phase 3 Data on Isunakinra (EBI-005) in Allergic Conjunctivitis 72
Dec 16, 2015: Aldeyra Therapeutics Announces Last Patient Dosed in Phase II Trial of NS2 in Patients with Allergic Conjunctivitis 73
Nov 24, 2015: Ocular Therapeutix Begins Enrollment in its Second Phase 3 Clinical Trial for DEXTENZA for the Treatment of Allergic Conjunctivitis 73
Nov 12, 2015: Ora-CAC Model Delivers Successful Phase 3 Data for Ocular Therapeutix's DEXTENZA for Treatment of Allergic Conjunctivitis 74
Oct 22, 2015: Ocular Therapeutix Announces Topline Results of Phase 3 Clinical Trial for DEXTENZA for the Treatment of Allergic Conjunctivitis 75
Oct 15, 2015: Eleven Biotherapeutics Completes Enrollment in Pivotal Phase 3 Study of Isunakinra (EBI-005) in Patients with Allergic Conjunctivitis 76
Sep 29, 2015: Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase IIa Clinical Trial 77
Aug 12, 2015: Eleven Biotherapeutics Announces First Patients Dosed with EBI-005 in Phase 3 Study in Patients with Moderate to Severe Allergic Conjunctivitis 77
Jun 16, 2015: Ocular Therapeutix Begins Enrollment in Phase 3 Clinical Trial for DEXTENZA for the Treatment of Allergic Conjunctivitis 78
Appendix 79
Methodology 79
Coverage 79
Secondary Research 79
Primary Research 79
Expert Panel Validation 79
Contact Us 79
Disclaimer 80
List of Tables
Number of Products under Development for Allergic Conjunctivitis, H1 2016 9
Number of Products under Development for Allergic Conjunctivitis - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Number of Products under Investigation by Universities/Institutes, H1 2016 12
Comparative Analysis by Late Stage Development, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Development, H1 2016 15
Products under Development by Companies, H1 2016 16
Products under Investigation by Universities/Institutes, H1 2016 17
Allergic Conjunctivitis - Pipeline by Accolade Pharmaceuticals, LLC, H1 2016 18
Allergic Conjunctivitis - Pipeline by Akari Therapeutics, Plc, H1 2016 19
Allergic Conjunctivitis - Pipeline by Aldeyra Therapeutics, Inc., H1 2016 20
Allergic Conjunctivitis - Pipeline by Allergan Plc, H1 2016 21
Allergic Conjunctivitis - Pipeline by Biogen, Inc., H1 2016 22
Allergic Conjunctivitis - Pipeline by Griffin Discoveries BV, H1 2016 23
Allergic Conjunctivitis - Pipeline by NicOx S.A., H1 2016 24
Allergic Conjunctivitis - Pipeline by Ocular Therapeutix, Inc., H1 2016 25
Allergic Conjunctivitis - Pipeline by Ohr Pharmaceutical Inc., H1 2016 26
Allergic Conjunctivitis - Pipeline by Sylentis S.A.U., H1 2016 27
Allergic Conjunctivitis - Pipeline by Xencor, Inc., H1 2016 28
Assessment by Monotherapy Products, H1 2016 29
Number of Products by Stage and Target, H1 2016 31
Number of Products by Stage and Mechanism of Action, H1 2016 33
Number of Products by Stage and Route of Administration, H1 2016 35
Number of Products by Stage and Molecule Type, H1 2016 37
Allergic Conjunctivitis Therapeutics - Recent Pipeline Updates, H1 2016 55
Allergic Conjunctivitis - Dormant Projects, H1 2016 69
Allergic Conjunctivitis - Dormant Projects (Contd..1), H1 2016 70
Allergic Conjunctivitis - Discontinued Products, H1 2016 71
List of Figures
Number of Products under Development for Allergic Conjunctivitis, H1 2016 9
Number of Products under Development for Allergic Conjunctivitis - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Comparative Analysis by Late Stage Development, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Products, H1 2016 15
Assessment by Monotherapy Products, H1 2016 29
Number of Products by Top 10 Targets, H1 2016 30
Number of Products by Stage and Top 10 Targets, H1 2016 30
Number of Products by Mechanism of Actions, H1 2016 32
Number of Products by Stage and Mechanism of Actions, H1 2016 32
Number of Products by Routes of Administration, H1 2016 34
Number of Products by Stage and Routes of Administration, H1 2016 34
Number of Products by Molecule Types, H1 2016 36
Number of Products by Stage and Molecule Types, H1 2016 36
